Department of Psychiatry and Behavioral Sciences, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA.
Department of Psychiatry and Behavioral Sciences, Behavioral Pharmacology Research Unit, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD 21224, USA; Friends Research Institute, 1040 Park Avenue, Suite 103, Baltimore, MD 21201, USA.
Psychiatr Clin North Am. 2022 Sep;45(3):515-528. doi: 10.1016/j.psc.2022.05.006. Epub 2022 Jul 31.
The US opioid crisis and the COVID-19 pandemic have sparked innovation in substance use disorder (SUD) treatment such that telehealth, remote monitoring, and digital health interventions are increasingly feasible and effective. These technologies can increase SUD treatment access and acceptability, even for nontreatment seeking, remote, and underserved populations, and can be used to reduce health disparities. Overall, digital tools will likely overcome many barriers to delivery of evidence-based behavioral treatments such as cognitive behavioral therapy and contingency management, that, along with appropriate medications, constitute the foundation of treatment of SUDs.
美国阿片类药物危机和 COVID-19 大流行促使物质使用障碍(SUD)治疗领域的创新,使得远程医疗、远程监测和数字健康干预措施越来越可行和有效。这些技术可以增加 SUD 治疗的可及性和可接受性,即使对于非治疗寻求、偏远和服务不足的人群也是如此,并且可以用来减少健康差距。总的来说,数字工具可能会克服提供基于证据的行为治疗(如认知行为疗法和依情况处理)的许多障碍,这些治疗方法与适当的药物一起构成了 SUD 治疗的基础。